Acta dermato-venereologica最新文献_第7页

Dupilumab Achieves Early Disease Control in Bullous Pemphigoid: A Case Series with TARC-based Biomarker Evaluation. Dupilumab实现大疱性类天疱疮的早期疾病控制：基于tarc的生物标志物评估的病例系列

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-07-01 DOI: 10.2340/actadv.v105.43999

Saori Takamura, Tomoo Fukuda

引用次数: 0

Exploring the Risk of Alcohol Addiction and Substance Use Disorders in Darier Disease and Hailey-Hailey Disease. 探索酒精成瘾和物质使用障碍的风险达里尔病和海莉病。

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-06-25 DOI: 10.2340/actadv.v105.43756

William Jebril, Philip Curman, Berta Olafsdottir, Etty Bachar-Wikström, Jakob Wikström

引用次数: 0

Hospital Use, Morbidity, and Cancer Risk by Age Group in Neurofibromatosis Type 1: A Nationwide Retrospective Cohort Study. 1型神经纤维瘤病的住院情况、发病率和癌症风险：一项全国回顾性队列研究

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-06-25 DOI: 10.2340/actadv.v105.43416

Minsu Kim, Suhyun Han, Chong Won Choi, Bo Ri Kim, Sang Woong Youn

{"title":"Hospital Use, Morbidity, and Cancer Risk by Age Group in Neurofibromatosis Type 1: A Nationwide Retrospective Cohort Study.","authors":"Minsu Kim, Suhyun Han, Chong Won Choi, Bo Ri Kim, Sang Woong Youn","doi":"10.2340/actadv.v105.43416","DOIUrl":"10.2340/actadv.v105.43416","url":null,"abstract":"Neurofibromatosis type 1 (NF1) affects multiple organs progressively, leading to a shortened life expectancy. This study aimed to identify the complications that are prominent in each age group by comparing 28,082 patients with NF1 and 84,246 matched controls. Benign and malignant neoplasms along with neurological complications were the primary contributors to hospital use across most age groups. Respiratory and circulatory disorders were a common cause of hospital use in children and older adults, respectively. Except for soft tissue and central nervous system-originated malignancies, which are well-established NF1-related tumours, the highest rate ratios (RR) of malignancies with statistical significance was observed in the adrenal gland (0-9 years, RR 50.67, 95% CI 6.74-380.76); female genital organs (10-14 years, RR 12.06, 95% CI 1.35-107.93); respiratory and intrathoracic organs (15-19 years, RR 15.10, 95% CI 1.76-129.22; 20-29 years, RR 7.59, 95% CI 2.94-19.56; ≥ 60 years, RR 1.38, 95% CI 1.18-1.61); lip, oral cavity, and pharynx (30-39 years, RR 6.11, 95% CI 1.53-24.42); and bone and articular cartilage (40-49 years, RR 3.06, 95% CI 1.37-6.81; 50-59 years, RR 4.73, 95% CI 2.35-9.50). Comorbidities and malignancies that predominantly affect patients vary by age group; physicians should be aware of the appropriate management strategies throughout their lifespan.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv43416"},"PeriodicalIF":3.5,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12228043/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144482825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful Control of Refractory Hidradenitis Suppurativa with Spesolimab: A Case Report. Spesolimab成功控制难治性化脓性汗腺炎1例。

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-06-23 DOI: 10.2340/actadv.v105.43329

Yangfan Lai, Yanzhuo Hu, Xiaoyao Fan, Baishuang Yue, Ying Ma

引用次数: 0

Association of Male Androgenetic Alopecia with Psychosocial and Sexual Well-being in Early Middle-aged Men: A Northern Finland Birth Cohort 1986 Study. 男性雄激素性脱发与中年早期男性社会心理和性健康的关系：1986年芬兰北部出生队列研究。

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-06-23 DOI: 10.2340/actadv.v105.43457

Arttu Järvinen, Jari Jokelainen, Laura Huilaja, Suvi-Päivikki Sinikumpu

{"title":"Association of Male Androgenetic Alopecia with Psychosocial and Sexual Well-being in Early Middle-aged Men: A Northern Finland Birth Cohort 1986 Study.","authors":"Arttu Järvinen, Jari Jokelainen, Laura Huilaja, Suvi-Päivikki Sinikumpu","doi":"10.2340/actadv.v105.43457","DOIUrl":"10.2340/actadv.v105.43457","url":null,"abstract":"Androgenetic alopecia is the most common type of hair loss in men. It is reported to have a strong effect on the quality of life, especially at a young age. However, there are only a few studies evaluating the relationship between androgenetic alopecia and psychosocial well-being in the general population. This study examined the association of androgenetic alopecia and its severity with psychosocial symptoms and sexual issues at a population level in male subjects aged between 33 and 35 years belonging to the Northern Finland Birth Cohort 1986 Study (NFBC1986) (n = 1,027). During 2019 to 2020, cohort subjects participated in a large follow-up study and completed diverse health questionnaires, including information on their hair status, psychosocial symptoms (the Hopkins Symptom Checklist-25 [HSCL-25] and the Generalized Anxiety Disorder Screener [GAD-7]) and sexual health. Androgenetic alopecia was reported as follows: No androgenetic alopecia n = 468 (45.6%), mild n = 435 (42.4%), moderate n = 62 (6.0%), and severe androgenetic alopecia n = 62 men (6.0%). There was no significant association of androgenetic alopecia presence or its severity with depression, anxiety, or sexual symptoms. In conclusion, contrary to previous findings, a relationship between androgenetic alopecia and psychosocial problems in early midlife was not found.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv43457"},"PeriodicalIF":3.5,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12215527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144473660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis. 不同种类生物制剂治疗牛皮癣的实际成本。

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-06-18 DOI: 10.2340/actadv.v105.42767

Linda T H Godding, Marieke M B Seyger, Albert Duvetorp, Marisol E Otero, Paul M Ossenkoppele, Annet M Oostveen, M Birgitte Visch, Ella A M Van der Voort, John E M Körver, Lizelotte J M T Weppner-Parren, Maartje A M Berends, W Peter Arnold, Sharon R P Dodemont, Astrid L A Kuijpers, Johannes M Mommers, Femke M Homan, Antoni H Gostynski, Berit Velstra, Marloes M Kleinpenning, Martijn B A Van Doorn, Romy R M C Keijsers, Else N Kop, Inge M Haeck, Judith H J Hendricksen-Roelofzen, Douwe Vellinga, Elke M G J De Jong, Juul M P A Van den Reek

{"title":"Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis.","authors":"Linda T H Godding, Marieke M B Seyger, Albert Duvetorp, Marisol E Otero, Paul M Ossenkoppele, Annet M Oostveen, M Birgitte Visch, Ella A M Van der Voort, John E M Körver, Lizelotte J M T Weppner-Parren, Maartje A M Berends, W Peter Arnold, Sharon R P Dodemont, Astrid L A Kuijpers, Johannes M Mommers, Femke M Homan, Antoni H Gostynski, Berit Velstra, Marloes M Kleinpenning, Martijn B A Van Doorn, Romy R M C Keijsers, Else N Kop, Inge M Haeck, Judith H J Hendricksen-Roelofzen, Douwe Vellinga, Elke M G J De Jong, Juul M P A Van den Reek","doi":"10.2340/actadv.v105.42767","DOIUrl":"10.2340/actadv.v105.42767","url":null,"abstract":"Although biologics have revolutionized psoriasis treatment, they pose a significant burden on the healthcare budget. With the wide range of biologics available and the increasing number of biosimilars, insights into the real-world cost per responder (CPR) are required. Therefore, this study aims to evaluate the real-world CPR of adalimumab, ustekinumab, IL17- and IL23-inhibitors, incorporating both relative (Psoriasis Area and Severity Index; PASI75/90/100) and absolute (PASI ≤ 3/ ≤ 1) responder definitions and real-world dose adjustments. Tildrakizumab and bimekizumab were excluded due to limited data. Using Dutch list prices and discounts on adalimumab's and ustekinumab's originator prices because of biosimilar availability, adalimumab showed the lowest 1-year CPR across all responder definitions. Among biologics without biosimilar availability, the lowest CPRs were seen for brodalumab and guselkumab. Overall, the cost-per-PASI ≤ 3-responder was, across all biologics, more homogeneous than the CPR based on relative PASIs. Similar patterns were seen when using Swedish prices, which are, in contrast to Dutch prices, transparent. The relevance of using real-world data, specifically with the use of absolute PASIs instead of relative PASIs, is shown in this study. Additionally, as price fluctuations have the biggest impact on cost-effectiveness, price transparency is essential to effectively guide physicians in selecting a cost-effective treatment strategy.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv42767"},"PeriodicalIF":3.5,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12186437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144324138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Four Cases of Prurigo Nodularis Requiring Nemolizumab due to Persistent Pruritus or Lesions after Dupilumab Treatment. 杜匹单抗治疗后持续性瘙痒或病变需要奈莫单抗治疗的结节性痒疹4例

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-06-16 DOI: 10.2340/actadv.v105.43419

Yoshihito Mima, Masako Yamamoto, Ken Iozumi